Asthma drug may shield kidneys in young diabetics
NCT ID NCT07409714
First seen Feb 16, 2026 · Last updated May 20, 2026 · Updated 11 times
Summary
This study tests montelukast, an asthma drug, in 50 teens and young adults (ages 14–24) with type 2 diabetes. The goal is to see if it can reduce inflammation that damages kidneys and blood vessels. Participants will take the drug for 6 months, and researchers will measure changes in kidney and heart function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.